Surface Oncology Inc

+0.06 (+5.77%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)63.84M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.1 Million
Adjusted EPS-$0.46
See more estimates
10-Day MA$1.11
50-Day MA$1.48
200-Day MA$2.52
See more pivots

Surface Oncology Inc Stock, NASDAQ:SURF

50 Hampshire Street, 8th floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.714.4096
Number of Employees: 67


Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firmâ??s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.